drugset / Trial / NCT04051268

Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)

NCT04051268

Phase 3 Completed 3071 enrolled PT Bio Farma
RandomizedParallel-groupDouble-blindPrevention

Summary

Phase III study, Randomized, observer blind, lot to lot consistency, non inferiority to PQed typhoid conjugate vaccine and Typhoid Vi polysaccharide vaccine.

Timeline

Start
2020-03-02
Primary completion
2021-11-24
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator PQed Typhoid Conjugate Vaccine Vaccine 0.5 ml
Comparator Vi Polysaccharide Vaccine Vaccine 0.5 ml
Subject Vi-DT Typhoid Conjugate Vaccine Vaccine 0.5 ml

Indications

No indication recorded.